This review summarizes recent advances in our understanding of p53 and Rb aberrations, their functional significance in the pathobiology of SCLC development and progression, and their potential clinical application, emphasizing completed and ongoing clinical trials with various therapeutic agents that target dysregulated downstream signaling pathways. This evidence concerns the gene RB1 and small cell lung carcinoma.